Disparity between scientific accomplishment and biotechnology availability in Brazil

Lucia Maria Almeida Braz¹, Roozbeh Tahmasebi¹, Antonio Charlys da Costa¹ and Steven S Witkin¹,²
¹Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brasil
²Weill Cornell Medicine, New York, NY, USA

Abstract
Despite being among the world's leaders in scientific output, Brazil ranks 66th among countries in the production of reagents and supplies needed for state-of-the-art scientific analyses. The production of needed reagents and equipment for experimental analyses and patient diagnostics is sorely lacking within Brazil and explicit in this pandemic period caused by SARS-CoV-2. A significant fraction of resources from Brazilian funding agencies is now being transferred to companies in other countries for the purchase of essential scientific-related products. Is this sustainable? Therefore it is necessary to draw the attention of all the world and Brazilian society about this situation

Keywords
Brazilian biotechnology, Brazilian entrepreneurs, Brazilian scientists, Neglected technological investment, for-profit industries, start-up companies

Brazilian scientists are among the world leaders in biomedical research and development. For example, by mid-October 2020, Brazilian researchers have published 4000 scientific articles on the SARS-CoV-2 pandemic. This attests to the high degree of competence amongst Brazilian scientists.¹ However, in marked contrast to the exceptionalism of the country's scientific community, there remains an insufficient investment in biotechnology. The production within Brazil of reagents and

Corresponding author:
Lucia Maria Almeida Braz, Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, Av.do.eneas Carvalho de Aguiar, 470/500, São Paulo 01246-903, Brasil.
Email: lmabraz@usp.br

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
equipment needed for experimental analyses and patient diagnostics is sorely lacking. To maintain a high level of scientific output to effectively satisfy the national demands of a country with 220 million people an adequate investment in technological investment is paramount.

Despite it being among the world’s leaders in scientific output, Brazil ranks 66th among countries in the production of reagents and supplies needed for state-of-the-art scientific analyses, according to Benedito Aguiar, ex-president of CAPES (Coordination for the Improvement of Higher Education Personnel). Therefore, Brazilian scientists are extremely dependent on other countries both for the development of biotechnological advances and for the availability and purchase of reagents and equipment that have become indispensable for the performance of productive research. This also holds true for the identification and development of diagnostics for the differential identification of multiple clinical illnesses and syndromes.

One of the most rapidly advancing technologies that is revolutionizing molecular diagnoses as well as the analysis of disease mechanisms involves nucleic acid amplification, modification and sequence identification. Currently, critical supplies to perform the relevant assays, as well as the equipment to analyse the experimental data, have to be imported. Major sources of critical supplies include companies in the United States, China, Japan, United Kingdom, Germany and France. The current relatively weak Brazilian economy and low exchange rate further hinders the ability of scientific researchers to import adequate quantities of essential supplies. This deficiency in technological availability is strongly reflected in the absence of Brazil’s participation in the production of a vaccine against SARS-CoV-2.

There is an urgent need for internal financing by Brazilian agencies such as FAPESP, CNPQ, FINEP to stimulate national entrepreneurship in biotechnology, especially associated with the laboratory products industry. In its absence, a significant fraction of resources from Brazilian funding agencies are now being transferred to companies in other countries for the purchase of essential scientific-related products. Is this sustainable? An investment in Brazilian biotechnology to develop laboratory diagnostics will be beneficial in multiple areas such as the production of vaccines, development of medicines and monitoring of treatments. In addition, the availability of financing will enable the initiation of start-up companies and attract the participation of Brazilian entrepreneurs in the development and expansion of for-profit industries. Efforts to integrate academia with the business sector will lead to a more rapid advancement of scientific knowledge in Brazil but also will provide added economic value to that knowledge, which will be beneficial to the well-being of the entire country.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iDs**

Lucia Maria Almeida Braz [https://orcid.org/0000-0002-6493-465X](https://orcid.org/0000-0002-6493-465X)

Roozbeh Tahmasebi [https://orcid.org/0000-0001-9631-5530](https://orcid.org/0000-0001-9631-5530)

**References**

1. Ioannidis JPA, Boyack KW and Baas J. Updated science-wide author databases of standardized citation indicators. *PLoS Biol* 2020; 18(10): e3000918.

2. Brasil em Pauta entrevista o presidente da Capes, Benedito Aguiar. *TV Brasil*. [https://tvbrasil.ebc.com.br/brasil-em-pauta/2020/11/brasil-em-pauta-entrevista-o-presidente-da-capes-benedito-aguiar](https://tvbrasil.ebc.com.br/brasil-em-pauta/2020/11/brasil-em-pauta-entrevista-o-presidente-da-capes-benedito-aguiar)

3. Kallas EG, D’Elia Zanella LGFAB, Moreira CHV, et al. Predictors of mortality in patients with yellow fever: an observational cohort study. *Lancet Infect Dis* 2019; 19: 750–758.

4. de Godoy NS, da Costa Lima MS Jr, Lindoso JAL, et al. A PCR and RFLP-based molecular diagnostic algorithm for visceral leishmaniasis. *Asian Pac J Trop Med* 2020; 13(2): 62–70.

5. de Jesus JG, Sacchi C, Candido DS, et al. Importation and early local transmission of COVID-19 in Brazil, 2020. *Rev Inst Med Trop Sao Paulo* 2020; 62: e30.

6. Ribeiro GO, Costa AC, Gill DE, et al. Guapiaçu virus, a new insect-specific flavivirus isolated from two species of *Aedes* mosquitoes from Brazil. *Sci Rep* 2021; 11: 4674.

7. Tozetto-Mendoza TR, Kanunfre KA, Vilas-Boas LS, et al. Nucleoprotein-based ELISA for detection of SARS-COV-2 IgG antibodies: could an old assay be suitable for serodiagnosis of the new coronavirus? *J Virol Methods* 2021; 290: 114064.

**Author biographies**

**Lucia Maria Almeida Braz** Biologist, with doctorate, of Instituto de Medicina Tropical de São Paulo, SP, FMUSP, Brazil. Researcher in the neglected tropical diseases as visceral and tegumentar leishmaniasis and Chagas disease. C.V. includes over 60 peer-reviewed publications in Chagas disease and leishmaniasis.

**Roozbeh Tahmasebi** Postdoctoral in the IMT/FMUSP with Fapesp grant.

**Antonio Charlys da Costa** Postdoctoral in the IMT/FMUSP with Fapesp grant. C.V. includes over 40 peer-reviewed publications in arboviroses.

**Steven S. Witkin** Professor Emeritus and formerly Distinguished Professor of Infection and Immunology in the Department of Obstetrics and Gynecology at Weill Cornell Medicine. Currently Visiting International Professor in the FMUSP-Lab.Inv.Medica-Virologia (LIM52)-Instituto de Medicina Tropical de São Paulo, São Paulo, Brazil. C.V. includes over 340 peer-reviewed publications in microbiology, immunology and genetics.